Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Abraham Jing-Ching Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2597-7091; OpenAlex author ID A5022293657. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  2. Multi-Institutional Comparison of Ablative 5-Fraction Magnetic Resonance-Guided Online Adaptive Versus 15/25-Fraction Computed Tomography-Guided Moderately Hyp… Co-author DOI 10.3390/cancers17152596↗
  3. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  4. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2023.03.036↗
  5. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Co-author DOI 10.1016/j.phro.2022.10.003↗
  6. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  7. Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection. Co-author DOI 10.1080/0284186x.2016.1245862↗
  8. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Last author DOI 10.1080/0284186x.2017.1342863↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marsha Reyngold · 7 shared papers, 2017–2025 · strength 1.03
  2. Christopher H. Crane · 7 shared papers, 2017–2025 · strength 1.03
  3. Carla Hajj · 7 shared papers, 2017–2025 · strength 0.96
  4. Eileen Mary O'Reilly · 7 shared papers, 2017–2025 · strength 0.95
  5. Kenneth H. Yu · 5 shared papers, 2017–2025 · strength 0.68
  6. Anna M. Varghese · 4 shared papers, 2021–2025 · strength 0.62
  7. Wungki Park · 4 shared papers, 2021–2025 · strength 0.62
  8. Danny N. Khalil · 4 shared papers, 2021–2025 · strength 0.62
  9. Zhigang Zhang · 5 shared papers, 2017–2025 · strength 0.59
  10. Karyn A. Goodman · 3 shared papers, 2017–2023 · strength 0.28
  11. Wei Lü · 1 shared paper, 2025 · strength 0.20
  12. Luis Alberto Diaz · 1 shared paper, 2025 · strength 0.20
  13. Michael David Chuong · 1 shared paper, 2025 · strength 0.20
  14. Kathryn Elizabeth Mittauer · 1 shared paper, 2025 · strength 0.20
  15. Adeel Kaiser · 1 shared paper, 2025 · strength 0.20
  16. Edward Christopher Dee · 1 shared paper, 2024 · strength 0.17
  17. Jeffrey A. Drebin · 1 shared paper, 2024 · strength 0.17
  18. William R. Jarnagin · 1 shared paper, 2024 · strength 0.17
  19. Alice Chia-Chi Wei · 1 shared paper, 2024 · strength 0.17
  20. Bernard L. Jones · 1 shared paper, 2023 · strength 0.15
  21. Amita Shukla‐Dave · 1 shared paper, 2023 · strength 0.15
  22. Shannan M. Dickinson · 1 shared paper, 2023 · strength 0.15
  23. Sana D. Karam · 1 shared paper, 2023 · strength 0.15
  24. Richard Kinh Gian Do · 1 shared paper, 2023 · strength 0.15
  25. Kathryn Ries Tringale · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.